Search
Close this search box.
Search
Close this search box.
Search
Close this search box.

South Africa

2024 Business School Applications Skyrocket amidst Economic Uncertainty

GMAC’s annual survey shows demand growth is five times greater than the pandemic boom RESTON, Va., Oct. 23, 2024 (GLOBE NEWSWIRE) — Across the globe, total applications to graduate business school programs in 2024 increased an impressive 12 percent from 2023 to 2024. This is a sharp reversal from the

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin’s innate glucosyltransferase in order to inhibit the toxin produced by C. diff. in the gastrointestinal tract. There are

Quantexa Recognized as Category Leader in the RiskTech Quadrant® for KYC Solutions

Quantexa earned a top ranking in the RiskTech100® 2025 Report, highlighting its strength and innovation in the expanding risk technology and compliance market LONDON, Oct. 22, 2024 (GLOBE NEWSWIRE) — Quantexa, a leading provider of Decision Intelligence solutions for public and private sectors, today announced it has received recognition in

Leil Storage: Green File Storage for Africa

Leil Storage for Africa TALLINN, Estonia, Oct. 21, 2024 (GLOBE NEWSWIRE) — In alignment with Africa Human Rights Day, Leil Storage announces the expansion of its Green Storage Initiative, an endeavor set to revolutionize file storage across Africa. This initiative underscores commitment to sustainability and affordability, promising a profound impact

Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset

The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV-011, a clinical Phase 1 investigational novel compound with broad potential to treat brain health diseases Cureverse receives undisclosed upfront payments and is eligible for future milestone-dependent payments and royalties, while retaining rights to commercialize

RECENT NEWS

Copyright © 2024 Pakistan Press Release Point. All rights reserved.